Neutrophils News and Research

RSS

Cellerant commences CLT-008 Phase I/II trial in patients with leukemia

Cellerant Therapeutics Inc., a biotechnology company developing novel hematopoietic stem cell-based cellular and antibody therapies for blood disorders and cancer, announced the initiation of a Phase I/II clinical trial of CLT-008 in patients receiving intensive post-remission chemotherapy for high-risk leukemia or myelodysplasia.

23 Mar 2011

CLL patients receive Biothera's new combination therapy in Phase I/II clinical trial

Patients with earlier stage high-risk Chronic Lymphocytic Leukemia recently began receiving a new combination treatment in a Phase I/II clinical trial that researchers believe could result in a more effective therapy for this disease, Biothera announced today.

15 Mar 2011

European Patent Office grants ProtAffin key patent for CellJammer discovery technology

ProtAffin AG, a biotechnology company developing novel biopharmaceuticals for respiratory disease, inflammation and oncology, today announced that it has been granted a key patent by the European Patent Office protecting its CellJammer® discovery technology, which enables the development of a new class of biopharmaceuticals.

14 Mar 2011

Researchers uncover new disease mechanism in patients with CGD

Infection researchers at Umeå University have uncovered a new disease mechanism in patients with Chronic Granulomatous Disease in an international clinical collaboration with the Children's Hospital in Zurich.

11 Mar 2011

Biothera announces acquisition of AS1402 anti-cancer monoclonal antibody from Antisoma

Biothera announced today that it has acquired the anti-cancer monoclonal antibody AS1402 from Antisoma for undisclosed terms.

10 Mar 2011

Compugen reports positive results from CGEN-25068 in animal model to treat certain disease conditions

Compugen Ltd. announced today positive animal model results for CGEN-25068, a novel peptide predicted and selected in silico to block a specific protein-protein interaction known to play an important role in various immune-related disease conditions.

8 Mar 2011

Dentists need to take a closer look at potential hazards of exposing patients to zinc

Dentists need to take a closer look at potential hazards of exposing patients to zinc, a common ingredient of many dental products, according to a report by Amar Patel, DDS, resident and colleagues at the University of Maryland Dental School in the March/April 2011 issue of the journal General Dentistry.

4 Mar 2011

New breakthrough in immunological research

Immunological research at the University of Haifa, Israel, has made a new breakthrough, revealing a critical component in the "decision-making" process of white blood cells that play a role in the healing process from bacterial inflammation.

3 Mar 2011

bcl3 gene limits lung injury during acute stress from illness, trauma, transplant

Lung injury is a common cause of death among patients with pneumonia, sepsis or trauma and in those who have had lung transplants. The damage often occurs suddenly and can cause life-threatening breathing problems and rapid lung failure.

9 Feb 2011

Researchers report promising new approach to treat diabetic wounds, bed sores

Loyola University Health System researchers are reporting on a promising new approach to treating diabetic wounds, bed sores, chronic ulcers and other slow-to-heal wounds.

8 Feb 2011

Scientists create 'reporter mouse' to close gap between kidney injury and diagnosis

The current check for kidney disease is a simple blood test for serum creatinine, but it can take longer than two days for this metabolite to accumulate to levels that are significant enough to indicate kidney damage - and by then it may be too late to intervene.

1 Feb 2011

Breakthrough in understanding mechanisms behind hereditary alpha-1-antitrypsin deficiency

Researchers from the Royal College of Surgeons in Ireland (RCSI) and Beaumont Hospital have made a breakthrough in understanding the mechanisms behind the most severe form of hereditary emphysema and how protein treatments can improve the condition. The findings of this study may also lead to new treatments for patients with smoker's emphysema.

24 Jan 2011

New way to halt lung inflammation

Acute inflammation of the lung is a poorly recognized human disease that develops in surprising and unexpected ways. The acute lung injury (ALI) or adult respiratory distress syndrome (ARDS) is a vital new concern for soldiers, but it can develop in anyone during a systemic infection, after severe trauma, as a result of bone fracture, following severe burns and in many other ways as well-- the initial cause may have nothing apparent to do with the lung itself.

18 Jan 2011

Celator, Cephalon extend cancer research agreement

Celator Pharmaceuticals today announced that it has agreed with Cephalon, Inc. to extend an existing research agreement into the next phase of development. The research agreement provides for the utilization of Celator's proprietary technology in an ongoing drug development and life-cycle management program at Cephalon.

10 Jan 2011

Blocking activation of delta-PKC enzyme could protect lungs from neutrophil-mediated damage

All of us may be able to breathe a little easier now that scientists from Pennsylvania have found a new therapeutic target for controlling dangerous inflammation in the lungs. A new research report in the January 2011 issue of the Journal of Leukocyte Biology (http://www.jleukbio.org) suggests that blocking the activation of an enzyme called delta-protein kinase C (delta-PKC) could protect the lungs from neutrophil-mediated damage, which can result in out of control inflammation.

5 Jan 2011

Increased amounts of MMP-1 enzyme may explain preeclampsia symptoms in pregnant women

Virginia Commonwealth University School of Medicine researchers have found that a significant increase of an enzyme in the blood vessels of pregnant women with preeclampsia may explain some of the symptoms associated with the condition, including hypertension, swelling and protein in the urine.

5 Jan 2011

New research sheds light on complex regulatory pathways for effective innate immune system

New research by scientists at the University of California, San Diego School of Medicine and Skaggs School of Pharmacy and Pharmaceutical Sciences reveals that the immune system has an effective backup plan to protect the body from infection when the "master regulator" of the body's innate immune system fails.

21 Dec 2010

Anchor Therapeutics announces publication describing pepducin technology as novel approach to target GPCR

Anchor Therapeutics today announced the publication of new research in the Proceedings of the National Academy of Sciences USA. The paper describes the identification and characterization of a pepducin-based allosteric agonist that targets CXCR4, a chemokine G protein-coupled receptor found on hematopoietic stem cells and other bone marrow-derived cells.

9 Dec 2010

Positive data from Celator's CPX-351 Phase 2 study in newly-diagnosed AML presented at 52nd ASH

Celator Pharmaceuticals today announced positive clinical data in elderly patients with newly-diagnosed acute myeloid leukemia (AML) treated with CPX-351 (Cytarabine:Daunorubicin) Liposome Injection. Data were presented from the podium at the 52nd American Society of Hematology (ASH) Annual Meeting in Orlando, Florida.

8 Dec 2010

Telik announces positive results from Phase 2 trial of ezatiostat in patients with MDS

Telik, Inc. today announced positive results from a Phase 2 multicenter trial of oral ezatiostat hydrochloride (TELINTRA, TLK199) in patients with an International Prognostic System Score of low to intermediate-1 risk myelodysplastic syndrome.

6 Dec 2010